BrightPath Biotherapeutics , Ltd. Profit Margin

BrightPath Biotherapeutics , Ltd. (4594.T) currently reports a profit margin of -2570440.32% as of June 2026. That compares with -93374.08% in the prior-year period — down 2652.8% year over year. That is below the Healthcare sector average of 19.13%. Use the charts on this page to explore BrightPath Biotherapeutics , Ltd.'s profit margin history and peer comparisons.

BrightPath Biotherapeutics , Ltd.'s profit margin decreased from -93374.08% to -2570440.32% — a 2652.8% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

BrightPath Biotherapeutics , Ltd.'s profit margin of -2570440.32% is lower than the Healthcare sector average of 19.13%. That is roughly 13435884.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but BrightPath Biotherapeutics , Ltd.'s current -2570440.32% should be judged against Healthcare norms (sector average: 19.13%) and against 4594.T's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -2570440.32%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 19.13%. From there, open related valuation or income-statement pages for BrightPath Biotherapeutics , Ltd., and consider following 4594.T for alerts when major investors trade the stock.